{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:10:39Z","timestamp":1794975039711,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2211051"],"award-info":[{"award-number":["W81XWH2211051"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["20B01"],"award-info":[{"award-number":["20B01"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    B cell-rich tertiary lymphoid structures (TLS) are associated with favorable prognosis and positive response to immunotherapy in cancer. Here we show that simultaneous activation of innate immune effectors, STING and lymphotoxin-\u03b2 receptor (LT\u03b2R), results in CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell-dependent tumor suppression while inducing high endothelial venule development and germinal center-like B cell responses in tumors to generate functional TLS in a T cell-dependent manner. In a neoadjuvant setting, activation of STING and LT\u03b2R by their agonists effectively immunized mice against tumor recurrence, leading to long-term survival. STING activation alone was insufficient for inducing B cell-containing TLS or eliciting long-term therapeutic effects. However, when combined with LT\u03b2R activation, it improved the fitness of TLS with B cell expansion and maturation to IgG-producing long-lived plasma cells and memory cells, increased CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell recruitment and memory CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell expansion, and shifted the T\n                    <jats:sub>H<\/jats:sub>\n                    2\/T\n                    <jats:sub>H<\/jats:sub>\n                    17 balance, resulting in the potentiation of humoral and cellular immunity against tumors. These findings suggest a therapeutic approach of simultaneously activating STING and lymphotoxin pathways.\n                  <\/jats:p>","DOI":"10.1038\/s41590-025-02259-8","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:04:33Z","timestamp":1756803873000},"page":"1766-1780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Simultaneous STING and lymphotoxin-\u03b2 receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-7037","authenticated-orcid":false,"given":"Junko","family":"Sawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7210-3825","authenticated-orcid":false,"given":"Yasuhiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Duah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-1089","authenticated-orcid":false,"given":"Krisztian","family":"Csomos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Stansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-4385","authenticated-orcid":false,"given":"Nobuyoshi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-0703","authenticated-orcid":false,"given":"Jolan","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-418X","authenticated-orcid":false,"given":"Carl F.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-137X","authenticated-orcid":false,"given":"Masanobu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2259_CR1","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","volume":"71","author":"L Martinet","year":"2011","unstructured":"Martinet, L. et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71, 5678\u20135687 (2011).","journal-title":"Cancer Res."},{"key":"2259_CR2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4161\/onci.19787","volume":"1","author":"L Martinet","year":"2012","unstructured":"Martinet, L., Garrido, I. & Girard, J. P. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology 1, 789\u2013790 (2012).","journal-title":"Oncoimmunology"},{"key":"2259_CR3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4161\/onci.20492","volume":"1","author":"L Martinet","year":"2012","unstructured":"Martinet, L. et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 1, 829\u2013839 (2012).","journal-title":"Oncoimmunology"},{"key":"2259_CR4","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"2259_CR5","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/bjc.2015.145","volume":"112","author":"N Hiraoka","year":"2015","unstructured":"Hiraoka, N. et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782\u20131790 (2015).","journal-title":"Br. J. Cancer"},{"key":"2259_CR6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2259_CR7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fimmu.2016.00244","volume":"7","author":"N Hiraoka","year":"2016","unstructured":"Hiraoka, N., Ino, Y. & Yamazaki-Itoh, R. Tertiary lymphoid organs in cancer tissues. Front Immunol. 7, 244 (2016).","journal-title":"Front Immunol."},{"key":"2259_CR8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"2259_CR9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"2259_CR10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"2259_CR11","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-19-3416","volume":"26","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. The immunosuppressive niche of soft-tissue sarcomas is sustained by tumor-associated macrophages and characterized by intratumoral tertiary lymphoid structures. Clin. Cancer Res. 26, 4018\u20134030 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2259_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1126\/science.8171322","volume":"264","author":"P De Togni","year":"1994","unstructured":"De Togni, P. et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703\u2013707 (1994).","journal-title":"Science"},{"key":"2259_CR13","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.4049\/jimmunol.161.12.6853","volume":"161","author":"CA Cuff","year":"1998","unstructured":"Cuff, C. A. et al. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J. Immunol. 161, 6853\u20136860 (1998).","journal-title":"J. Immunol."},{"key":"2259_CR14","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.4049\/jimmunol.162.10.5965","volume":"162","author":"CA Cuff","year":"1999","unstructured":"Cuff, C. A., Sacca, R. & Ruddle, N. H. Differential induction of adhesion molecule and chemokine expression by LTalpha3 and LTalphabeta in inflammation elucidates potential mechanisms of mesenteric and peripheral lymph node development. J. Immunol. 162, 5965\u20135972 (1999).","journal-title":"J. Immunol."},{"key":"2259_CR15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1074-7613(00)80292-7","volume":"6","author":"PA Koni","year":"1997","unstructured":"Koni, P. A. et al. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6, 491\u2013500 (1997).","journal-title":"Immunity"},{"key":"2259_CR16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.184.5.1999","volume":"184","author":"PD Rennert","year":"1996","unstructured":"Rennert, P. D., Browning, J. L., Mebius, R., Mackay, F. & Hochman, P. S. Surface lymphotoxin alpha\/beta complex is required for the development of peripheral lymphoid organs. J. Exp. Med. 184, 1999\u20132006 (1996).","journal-title":"J. Exp. Med."},{"key":"2259_CR17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1074-7613(02)00423-5","volume":"17","author":"E Dejardin","year":"2002","unstructured":"Dejardin, E. et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-\u03baB pathways. Immunity 17, 525\u2013535 (2002).","journal-title":"Immunity"},{"key":"2259_CR18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2014.02.002","volume":"25","author":"JL Gommerman","year":"2014","unstructured":"Gommerman, J. L., Browning, J. L. & Ware, C. F. The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity. Cytokine Growth Factor Rev. 25, 139\u2013145 (2014).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2259_CR19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.coi.2013.01.001","volume":"25","author":"RL Bjordahl","year":"2013","unstructured":"Bjordahl, R. L., Steidl, C., Gascoyne, R. D. & Ware, C. F. Lymphotoxin network pathways shape the tumor microenvironment. Curr. Opin. Immunol. 25, 222\u2013229 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"2259_CR20","doi-asserted-by":"crossref","first-page":"a016279","DOI":"10.1101\/cshperspect.a016279","volume":"7","author":"J Sedy","year":"2014","unstructured":"Sedy, J., Bekiaris, V. & Ware, C. F. Tumor necrosis factor superfamily in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 7, a016279 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2259_CR21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4049\/jimmunol.160.1.485","volume":"160","author":"R Sacca","year":"1998","unstructured":"Sacca, R., Cuff, C. A., Lesslauer, W. & Ruddle, N. H. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J. Immunol. 160, 485\u2013491 (1998).","journal-title":"J. Immunol."},{"key":"2259_CR22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature10540","volume":"479","author":"C Moussion","year":"2011","unstructured":"Moussion, C. & Girard, J. P. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479, 542\u2013546 (2011).","journal-title":"Nature"},{"key":"2259_CR23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2016.08.011","volume":"30","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 30, 500 (2016).","journal-title":"Cancer Cell"},{"key":"2259_CR24","doi-asserted-by":"publisher","unstructured":"Allen, E. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679 (2017).","DOI":"10.1126\/scitranslmed.aak9679"},{"key":"2259_CR25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ni.3836","volume":"18","author":"A Johansson-Percival","year":"2017","unstructured":"Johansson-Percival, A. et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18, 1207\u20131217 (2017).","journal-title":"Nat. Immunol."},{"key":"2259_CR26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir, A. et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40, 318\u2013334 (2022).","journal-title":"Cancer Cell"},{"key":"2259_CR27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer Cell 40, 1600\u20131618 (2022).","journal-title":"Cancer Cell"},{"key":"2259_CR28","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ccell.2023.04.010","volume":"41","author":"M Ramachandran","year":"2023","unstructured":"Ramachandran, M. et al. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell 41, 1134\u20131151 (2023).","journal-title":"Cancer Cell"},{"key":"2259_CR29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li, T. & Chen, Z. J. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287\u20131299 (2018).","journal-title":"J. Exp. Med."},{"key":"2259_CR30","doi-asserted-by":"publisher","unstructured":"Khoo, L. T. & Chen, L. Y. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches. EMBO Rep. https:\/\/doi.org\/10.15252\/embr.201846935 (2018).","DOI":"10.15252\/embr.201846935"},{"key":"2259_CR31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus, A. et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 49, 754\u2013763 (2018).","journal-title":"Immunity"},{"key":"2259_CR32","doi-asserted-by":"publisher","unstructured":"Yum, S., Li, M., Fang, Y. & Chen, Z. J. TBK1 recruitment to STING activates both IRF3 and NF-kappaB that mediate immune defense against tumors and viral infections. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2100225118 (2021).","DOI":"10.1073\/pnas.2100225118"},{"key":"2259_CR33","doi-asserted-by":"publisher","unstructured":"Chelvanambi, M., Fecek, R. J., Taylor, J. L. & Storkus, W. J. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001906 (2021).","DOI":"10.1136\/jitc-2020-001906"},{"key":"2259_CR34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2326-6066.CIR-21-0369","volume":"10","author":"J Sawada","year":"2022","unstructured":"Sawada, J. et al. Molecular signature of tumor-associated high endothelial venules that can predict breast cancer survival. Cancer Immunol. Res. 10, 468\u2013481 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"2259_CR35","volume":"10","author":"KA Michaelis","year":"2019","unstructured":"Michaelis, K. A. et al. The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10, 4682 (2019).","journal-title":"Nat. Commun."},{"key":"2259_CR36","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211\u20135218 (1999).","journal-title":"J. Immunol."},{"key":"2259_CR37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.immuni.2012.05.031","volume":"37","author":"MA Koch","year":"2012","unstructured":"Koch, M. A. et al. T-bet+ Treg cells undergo abortive TH1 cell differentiation due to impaired expression of IL-12 receptor \u03b22. Immunity 37, 501\u2013510 (2012).","journal-title":"Immunity"},{"key":"2259_CR38","doi-asserted-by":"publisher","unstructured":"Leonard, W. J. & Wan, C. K. IL-21 signaling in immunity. F1000Research https:\/\/doi.org\/10.12688\/f1000research.7634.1 (2016).","DOI":"10.12688\/f1000research.7634.1"},{"key":"2259_CR39","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/2159-8290.CD-21-1658","volume":"12","author":"D Hao","year":"2022","unstructured":"Hao, D. et al. The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma. Cancer Discov. 12, 2626\u20132645 (2022).","journal-title":"Cancer Discov."},{"key":"2259_CR40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41577-024-00991-0","volume":"24","author":"DR Fooksman","year":"2024","unstructured":"Fooksman, D. R., Jing, Z. & Park, R. New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells. Nat. Rev. Immunol. 24, 461\u2013470 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2259_CR41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Junttila","year":"2018","unstructured":"Junttila, I. S. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front. Immunol. 9, 888 (2018).","journal-title":"Front. Immunol."},{"key":"2259_CR42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/317537","volume":"32","author":"B Spellberg","year":"2001","unstructured":"Spellberg, B. & Edwards, J. E. Jr. Type 1\/type 2 immunity in infectious diseases. Clin. Infect. Dis. 32, 76\u2013102 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"2259_CR43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","volume":"23","author":"D Zehn","year":"2022","unstructured":"Zehn, D., Thimme, R., Lugli, E., de Almeida, G. P. & Oxenius, A. Stem-like\u2019 precursors are the fount to sustain persistent CD8+ T cell responses. Nat. Immunol. 23, 836\u2013847 (2022).","journal-title":"Nat. Immunol."},{"key":"2259_CR44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.immuni.2010.08.002","volume":"33","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1. Immunity 33, 229\u2013240 (2010).","journal-title":"Immunity"},{"key":"2259_CR45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41577-021-00590-3","volume":"22","author":"L Kok","year":"2022","unstructured":"Kok, L., Masopust, D. & Schumacher, T. N. The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues. Nat. Rev. Immunol. 22, 283\u2013293 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2259_CR46","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra, J. C. et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825\u2013841 (2020).","journal-title":"Immunity"},{"key":"2259_CR47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541 (2022).","journal-title":"Immunity"},{"key":"2259_CR48","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio, F. R. et al. Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice. Cell Mol. Gastroenterol. Hepatol. 12, 1543\u20131565 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2259_CR49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.182.1.5","volume":"182","author":"J Stavnezer","year":"2009","unstructured":"Stavnezer, J. & Kang, J. The surprising discovery that TGF beta specifically induces the IgA class switch. J. Immunol. 182, 5\u20137 (2009).","journal-title":"J. Immunol."},{"key":"2259_CR50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng, K. W. et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature 616, 563\u2013573 (2023).","journal-title":"Nature"},{"key":"2259_CR51","volume":"120","author":"SJ Im","year":"2023","unstructured":"Im, S. J. et al. Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer. Proc. Natl Acad. Sci. USA 120, e2221985120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2259_CR52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426418","volume":"15","author":"C Steiner","year":"2024","unstructured":"Steiner, C., Denlinger, N., Huang, X. & Yang, Y. Stem-like CD8+ T cells in cancer. Front Immunol. 15, 1426418 (2024).","journal-title":"Front Immunol."},{"key":"2259_CR53","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.20181216","volume":"216","author":"AE Denton","year":"2019","unstructured":"Denton, A. E. et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J. Exp. Med. 216, 621\u2013637 (2019).","journal-title":"J. Exp. Med."},{"key":"2259_CR54","doi-asserted-by":"crossref","first-page":"10577","DOI":"10.1073\/pnas.0700591104","volume":"104","author":"J Rangel-Moreno","year":"2007","unstructured":"Rangel-Moreno, J., Moyron-Quiroz, J. E., Hartson, L., Kusser, K. & Randall, T. D. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl Acad. Sci. USA 104, 10577\u201310582 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2259_CR55","doi-asserted-by":"publisher","unstructured":"Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J. & Luke, J. J. STING agonists as cancer therapeutics. Cancers https:\/\/doi.org\/10.3390\/cancers13112695 (2021).","DOI":"10.3390\/cancers13112695"},{"key":"2259_CR56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","volume":"33","author":"EN Chin","year":"2023","unstructured":"Chin, E. N., Sulpizio, A. & Lairson, L. L. Targeting STING to promote antitumor immunity. Trends Cell Biol. 33, 189\u2013203 (2023).","journal-title":"Trends Cell Biol."}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02259-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T22:02:38Z","timestamp":1759183358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02259-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1038\/s41590-025-02259-8","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.F.W. is a co-inventor on patents related to this research (patent no. US 8,974,787). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}